These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27109950)

  • 21. An underappreciated problem in renal transplant recipients: anemia.
    Unal A; Sipahioglu MH; Akcakaya M; Tokgoz B; Sav T; Oymak O; Utas C
    Transplant Proc; 2008 Jun; 40(5):1399-403. PubMed ID: 18589116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial.
    Murbraech K; Massey R; Undset LH; Midtvedt K; Holdaas H; Aakhus S
    Clin Transplant; 2015 Aug; 29(8):678-84. PubMed ID: 25982053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoepidemiology of anemia in kidney transplant recipients.
    Winkelmayer WC; Kewalramani R; Rutstein M; Gabardi S; Vonvisger T; Chandraker A
    J Am Soc Nephrol; 2004 May; 15(5):1347-52. PubMed ID: 15100376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation.
    González E; Andrés A; Polanco N; Hernández A; Morales E; Hernandez E; Huerta A; Ortuño T; Gutiérrez Martínez E; Praga M; Morales JM
    Transplant Proc; 2009; 41(6):2332-3. PubMed ID: 19715911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation.
    Sinnamon KT; Courtney AE; Maxwell AP; McNamee PT; Savage G; Fogarty DG
    Nephrol Dial Transplant; 2007 Jul; 22(7):1969-73. PubMed ID: 17353209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials.
    Cooper M; Wiseman AC; Zibari G; McCague K; Kim Y; Geissler F; Nashan B
    Clin Transplant; 2013; 27(6):E625-35. PubMed ID: 24033455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid status and kidney transplantation outcomes.
    Papalia T; Greco R; Lofaro D; Mollica A; Bonofiglio R
    Transplant Proc; 2011 May; 43(4):1042-4. PubMed ID: 21620048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
    Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M
    Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R
    J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Incidence and management of anemia in renal transplantation: an observational-French study].
    Choukroun G; Deray G; Glotz D; Lebranchu Y; Dussol B; Bourbigot B; Lefrançois N; Cassuto-Viguier E; Toupance O; Hacen C; Lang P; Mazouz H; Martinez F
    Nephrol Ther; 2008 Dec; 4(7):575-83. PubMed ID: 18672417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anemia in pediatric renal transplant recipients.
    Kausman JY; Powell HR; Jones CL
    Pediatr Nephrol; 2004 May; 19(5):526-30. PubMed ID: 15007719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of everolimus in de novo renal recipients: initial experience in the Greek population.
    Papanikolaou V; Vrochides D; Margari P; Imvrios G; Papagiannis A; Giakoustidis D; Fouzas I; Antoniadis N; Ouzounidis N; Ntinas A; Vergoulas G; Miserlis G; Solonaki F; Takoudas D
    Transplant Proc; 2008 Nov; 40(9):3166-9. PubMed ID: 19010223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
    Krämer BK; Neumayer HH; Stahl R; Pietrzyk M; Krüger B; Pfalzer B; Bourbigot B; Campbell S; Whelchel J; Eris J; Vitko S; Budde K;
    Transplant Proc; 2005 Apr; 37(3):1601-4. PubMed ID: 15866684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of anemia in renal transplant patients: results from MOST, an observational trial.
    Fernández Fresnedo G; Palomar R; Rodrigo E; Ruiz JC; de Francisco AL; Cotorruelo JG; Arias M
    Transplant Proc; 2005 Nov; 37(9):3821-2. PubMed ID: 16386550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
    Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P; Russ G; Oberbauer R; Murgia MG; Tufveson G; Chapman J; Blancho G; Mota A; Grandaliano G; Campistol JM; Brault Y; Burke JT;
    Transpl Int; 2007 Sep; 20(9):754-60. PubMed ID: 17565578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.